Subscribe To
Nurix: advancing targeted protein modulation therapies
Nurix Therapeutics is advancing a unique therapeutic approach of targeted protein modulation. The Company's current focus is on cancer treatment and s...
November 21, 2021, 11:19 am
Nurix: advancing targeted protein modulation therapies
Nurix Therapeutics is advancing a unique therapeutic approach of targeted protein modulation. The Company's current focus is on cancer treatment and s...
November 21, 2021, 11:19 am
Nurix: advancing targeted protein modulation therapies
Nurix Therapeutics is advancing a unique therapeutic approach of targeted protein modulation. The Company's current focus is on cancer treatment and s...
November 21, 2021, 11:19 am
Natera announces new publication validating signatera® velocity metric to improve cancer management
AUSTIN, Texas, Oct. 11, 2021 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a leader in transforming care through genetic and cell-free DNA testing, to...
October 11, 2021, 8:33 am
Natera announces new publication validating signatera® velocity metric to improve cancer management
AUSTIN, Texas, Oct. 11, 2021 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a leader in transforming care through genetic and cell-free DNA testing, to...
October 11, 2021, 8:33 am
Natera announces new publication validating signatera® velocity metric to improve cancer management
AUSTIN, Texas, Oct. 11, 2021 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a leader in transforming care through genetic and cell-free DNA testing, to...
October 11, 2021, 8:33 am
Repare therapeutics reveals early efficacy data from lead program in solid tumor setting
Repare Therapeutics Inc (NASDAQ: RPTX) announced the presentation of preliminary Phase 1 monotherapy data from its Phase 1/2 TRESR trial of RP-3500...
October 11, 2021, 6:21 am
Repare therapeutics reveals early efficacy data from lead program in solid tumor setting
Repare Therapeutics Inc (NASDAQ: RPTX) announced the presentation of preliminary Phase 1 monotherapy data from its Phase 1/2 TRESR trial of RP-3500...
October 11, 2021, 6:21 am
Repare therapeutics reveals early efficacy data from lead program in solid tumor setting
Repare Therapeutics Inc (NASDAQ: RPTX) announced the presentation of preliminary Phase 1 monotherapy data from its Phase 1/2 TRESR trial of RP-3500...
October 11, 2021, 6:21 am
4d molecular therapeutics presents interim results from the ongoing 4d-125 phase 1/2 clinical trial in patients with advanced x-linked retinitis pigmentosa at the asrs annual meeting
EMERYVILLE, Calif., Oct. 10, 2021 (GLOBE NEWSWIRE) -- 4D molecular Therapeutics (Nasdaq: FDMT), a clini...
October 10, 2021, 3:50 pm
4d molecular therapeutics presents interim results from the ongoing 4d-125 phase 1/2 clinical trial in patients with advanced x-linked retinitis pigmentosa at the asrs annual meeting
EMERYVILLE, Calif., Oct. 10, 2021 (GLOBE NEWSWIRE) -- 4D molecular Therapeutics (Nasdaq: FDMT), a clini...
October 10, 2021, 3:50 pm
4d molecular therapeutics presents interim results from the ongoing 4d-125 phase 1/2 clinical trial in patients with advanced x-linked retinitis pigmentosa at the asrs annual meeting
EMERYVILLE, Calif., Oct. 10, 2021 (GLOBE NEWSWIRE) -- 4D molecular Therapeutics (Nasdaq: FDMT), a clini...
October 10, 2021, 3:50 pm
Should you buy chemocentryx stock as shares spike 70% on avacopan approval?
On Friday, ChemoCentryx Inc. (NASDAQ:CCXI) shares spiked nearly 70% after announcing the Food and Drug Administration (FDA) had approved avacopan for ...
October 8, 2021, 4:30 pm
Should you buy chemocentryx stock as shares spike 70% on avacopan approval?
On Friday, ChemoCentryx Inc. (NASDAQ:CCXI) shares spiked nearly 70% after announcing the Food and Drug Administration (FDA) had approved avacopan for ...
October 8, 2021, 4:30 pm
Should you buy chemocentryx stock as shares spike 70% on avacopan approval?
On Friday, ChemoCentryx Inc. (NASDAQ:CCXI) shares spiked nearly 70% after announcing the Food and Drug Administration (FDA) had approved avacopan for ...
October 8, 2021, 4:30 pm
Repare therapeutics presents preliminary phase 1 monotherapy clinical data from the ongoing first-in-human phase 1/2 tresr study of rp-3500 in solid tumors at aacr-nci-eortc international conference o
CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage pr...
October 8, 2021, 3:10 pm
Repare therapeutics presents preliminary phase 1 monotherapy clinical data from the ongoing first-in-human phase 1/2 tresr study of rp-3500 in solid tumors at aacr-nci-eortc international conference o
CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage pr...
October 8, 2021, 3:10 pm
Repare therapeutics presents preliminary phase 1 monotherapy clinical data from the ongoing first-in-human phase 1/2 tresr study of rp-3500 in solid tumors at aacr-nci-eortc international conference o
CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage pr...
October 8, 2021, 3:10 pm
Relay therapeutics highlights interim data from bile duct cancer trial
Relay Therapeutics Inc (NASDAQ: RLAY) has announced an interim data Phase 1 trial of RLY-4008 in FGFR2-altered cholangiocarcinoma (bile duct cancer...
October 8, 2021, 12:24 pm
Relay therapeutics highlights interim data from bile duct cancer trial
Relay Therapeutics Inc (NASDAQ: RLAY) has announced an interim data Phase 1 trial of RLY-4008 in FGFR2-altered cholangiocarcinoma (bile duct cancer...
October 8, 2021, 12:24 pm